The CA5B antibody targets carbonic anhydrase 5B (CA-VB), a mitochondrial enzyme encoded by the *CA5B* gene. Carbonic anhydrases (CAs) catalyze the reversible hydration of carbon dioxide to bicarbonate and protons, playing critical roles in pH regulation, ion transport, and metabolic pathways. CA5B, part of the alpha-CA family, is primarily expressed in metabolic tissues like the liver, pancreas, and kidneys, where it supports gluconeogenesis, ureagenesis, and mitochondrial respiration by maintaining acid-base balance.
Research on CA5B has gained interest due to its potential links to metabolic disorders and cancer. Studies suggest its dysregulation may influence tumor microenvironment pH, impacting cancer progression and drug resistance. For example, CA5B overexpression has been observed in certain renal carcinomas, highlighting its possible role as a biomarker or therapeutic target.
CA5B antibodies are essential tools for detecting protein expression and localization in cells or tissues via techniques like Western blot, immunohistochemistry, or immunofluorescence. They enable investigations into CA5B's physiological functions and pathological relevance, particularly in mitochondrial metabolism and disease mechanisms. Recent studies also explore its involvement in rare genetic disorders linked to CA5B mutations, such as hyperammonemia. As CA isoforms often exhibit functional redundancy, CA5B-specific antibodies help dissect its unique contributions, advancing understanding of metabolic regulation and disease pathways.